BIIB
Biogen Inc.
Price Chart
Latest Quote
$195.34
-1.11 (-0.57%)
Current Price
| Previous Close | $196.45 |
| Open | $196.45 |
| Day High | $200.66 |
| Day Low | $195.23 |
| Volume | 854,112 |
Stock Information
| Shares Outstanding | 147.64M |
| Total Debt | $6.56B |
| Cash Equivalents | $4.28B |
| Revenue | $9.94B |
| Net Income | $1.37B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $28.84B |
| P/E Ratio | 21.03 |
| EPS (TTM) | $9.29 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $31.28B |
| Sales | $9.94B |
| Income | $1.37B |
| Book/sh | $126.37 |
| Cash/sh | $29.01 |
| Employees | 8K |
Financial Ratios
| Quick Ratio | 2.02 |
| Current Ratio | 3.06 |
| Debt/Eq | 35.18 |
| EPS Growth TTM | 32.80% |
Returns & Margins
| ROA | 5.95% |
| ROE | 7.70% |
| Gross Margin | 78.72% |
| Operating Margin | 22.90% |
| Profit Margin | 13.80% |
Ownership
| Insider Ownership | 0.17% |
| Institutional Ownership | 96.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 11.77 |
| PEG | 3.94 |
| P/S | 2.90 |
| P/B | 1.55 |
Analyst Data
| Recommendation | buy |
| Target Price | $219.44 |
Technical Indicators
| SMA20 | $194.22 |
| SMA50 | $187.66 |
| SMA200 | $171.98 |
| RSI | 53.67 |
| ATR | 5.1591 |
| Shares Float | 147.20M |
| Short Float | 3.57% |
| Short Ratio | 3.93 |
| Volatility | 0.18 |
| Rel Volume | 0.73 |
Performance History
| Week | -0.34% |
| Month | +2.44% |
| Quarter | +5.66% |
| 6 Months | +8.07% |
| YTD | +9.85% |
| Year | +48.14% |
| 3 Years | -34.10% |
| 5 Years | -26.97% |
| 10 Years | -32.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $195.34 | 854,112 |
| 2026-06-04 | $196.45 | 719,100 |
| 2026-06-03 | $195.96 | 891,500 |
| 2026-06-02 | $188.83 | 1,097,800 |
| 2026-06-01 | $192.23 | 841,500 |
| 2026-05-29 | $196.00 | 1,905,400 |
| 2026-05-28 | $196.39 | 556,200 |
| 2026-05-27 | $196.97 | 893,000 |
| 2026-05-26 | $193.08 | 930,100 |
| 2026-05-22 | $193.76 | 892,900 |
| 2026-05-21 | $189.47 | 1,475,200 |
| 2026-05-20 | $187.80 | 919,700 |
| 2026-05-19 | $190.56 | 1,054,100 |
| 2026-05-18 | $191.91 | 1,051,300 |
| 2026-05-15 | $192.95 | 1,252,200 |
| 2026-05-14 | $191.37 | 2,812,900 |
| 2026-05-13 | $204.53 | 1,271,900 |
| 2026-05-12 | $199.36 | 1,145,400 |
| 2026-05-11 | $197.95 | 1,772,200 |
| 2026-05-08 | $193.45 | 931,500 |
| 2026-05-07 | $191.38 | 735,600 |
| 2026-05-06 | $190.68 | 741,300 |
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Should Biogenâs (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?
Simply Wall St. âĸ 2026-06-05T20:04:51Z
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data
Simply Wall St. âĸ 2026-06-05T19:12:02Z
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Zacks âĸ 2026-06-05T16:04:00Z
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Zacks âĸ 2026-06-04T15:30:26Z
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
Zacks âĸ 2026-06-03T15:50:00Z
Getting Alzheimerâs Drugs Into the Brain Is Hard. Now Thereâs a New Trick.
Barrons.com âĸ 2026-06-03T07:30:00Z
Biogen Ends BIIB122 Parkinsons Trial And Refocuses Neurodegeneration Pipeline
Simply Wall St. âĸ 2026-06-02T10:07:31Z
Is COMPASS Pathways (CMPS) Quietly Recalibrating Its Commercialization Strategy With This Board Appointment?
Simply Wall St. âĸ 2026-06-02T09:13:17Z
Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report?
Zacks âĸ 2026-05-29T15:30:10Z
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
MarketBeat âĸ 2026-05-26T00:06:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,139,300,000 | $2,083,900,000 | $2,279,200,000 | $2,125,800,000 |
| Cost Of Revenue | $2,404,200,000 | $2,310,400,000 | $2,533,400,000 | $2,278,300,000 |
| Total Revenue | $9,890,600,000 | $9,675,900,000 | $9,835,600,000 | $10,173,400,000 |
| Operating Revenue | $9,890,600,000 | $9,675,900,000 | $9,835,600,000 | $9,688,300,000 |
| Expenses | ||||
| Interest Expense | $267,500,000 | $250,300,000 | $246,900,000 | $246,600,000 |
| Total Expenses | $7,421,600,000 | $7,395,500,000 | $7,987,900,000 | $7,271,500,000 |
| Other Income Expense | $-770,000,000 | $-191,700,000 | $-580,500,000 | $847,200,000 |
| Other Non Operating Income Expenses | $24,700,000 | $85,300,000 | $400,000 | $-10,100,000 |
| Net Non Operating Interest Income Expense | $-142,500,000 | $-182,700,000 | $29,600,000 | $-157,300,000 |
| Interest Expense Non Operating | $267,500,000 | $250,300,000 | $246,900,000 | $246,600,000 |
| Operating Expense | $5,017,400,000 | $5,085,100,000 | $5,454,500,000 | $4,993,200,000 |
| Other Operating Expenses | $290,200,000 | $254,400,000 | $218,800,000 | $-7,400,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,292,900,000 | $1,632,200,000 | $1,161,100,000 | $3,046,900,000 |
| Net Interest Income | $-142,500,000 | $-182,700,000 | $29,600,000 | $-157,300,000 |
| Interest Income | $125,000,000 | $67,600,000 | $276,500,000 | $89,300,000 |
| Normalized Income | $1,953,014,121 | $1,869,408,499 | $1,681,586,400 | $2,340,484,800 |
| Net Income From Continuing And Discontinued Operation | $1,292,900,000 | $1,632,200,000 | $1,161,100,000 | $3,046,900,000 |
| Net Income Common Stockholders | $1,292,900,000 | $1,632,200,000 | $1,161,100,000 | $3,046,900,000 |
| Net Income | $1,292,900,000 | $1,632,200,000 | $1,161,100,000 | $3,046,900,000 |
| Net Income Including Noncontrolling Interests | $1,292,900,000 | $1,632,200,000 | $1,161,500,000 | $2,961,600,000 |
| Net Income Continuous Operations | $1,292,900,000 | $1,632,200,000 | $1,161,500,000 | $2,961,600,000 |
| Pretax Income | $1,556,500,000 | $1,906,000,000 | $1,296,800,000 | $3,591,800,000 |
| Special Income Charges | $-746,400,000 | $-145,700,000 | $-239,300,000 | $1,170,100,000 |
| Interest Income Non Operating | $125,000,000 | $67,600,000 | $276,500,000 | $89,300,000 |
| Operating Income | $2,469,000,000 | $2,280,400,000 | $1,847,700,000 | $2,901,900,000 |
| Depreciation Amortization Depletion Income Statement | $515,000,000 | $446,700,000 | $240,600,000 | $365,900,000 |
| Depreciation And Amortization In Income Statement | $515,000,000 | $446,700,000 | $240,600,000 | $365,900,000 |
| Amortization Of Intangibles Income Statement | $515,000,000 | $446,700,000 | $240,600,000 | $365,900,000 |
| Gross Profit | $7,486,400,000 | $7,365,500,000 | $7,302,200,000 | $7,895,100,000 |
| Earnings From Equity Interest Net Of Tax | - | $0 | $0 | $2,600,000 |
| Total Operating Income As Reported | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 |
| Basic EPS | $8.83 | $11.21 | $8.02 | $20.96 |
| Other | ||||
| Tax Effect Of Unusual Items | $-134,585,879 | $-39,791,501 | $-60,413,600 | $150,884,800 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $3,398,600,000 | $3,106,500,000 | $2,619,400,000 | $3,499,500,000 |
| Total Unusual Items | $-794,700,000 | $-277,000,000 | $-580,900,000 | $857,300,000 |
| Total Unusual Items Excluding Goodwill | $-794,700,000 | $-277,000,000 | $-580,900,000 | $857,300,000 |
| Reconciled Depreciation | $779,900,000 | $673,200,000 | $494,800,000 | $518,400,000 |
| EBITDA (Bullshit earnings) | $2,603,900,000 | $2,829,500,000 | $2,038,500,000 | $4,356,800,000 |
| EBIT | $1,824,000,000 | $2,156,300,000 | $1,543,700,000 | $3,838,400,000 |
| Diluted Average Shares | $147,100,000 | $145,900,000 | $145,600,000 | $146,000,000 |
| Basic Average Shares | $146,500,000 | $145,600,000 | $144,700,000 | $145,300,000 |
| Diluted NI Availto Com Stockholders | $1,292,900,000 | $1,632,200,000 | $1,161,100,000 | $3,046,900,000 |
| Minority Interests | $0 | $0 | $-400,000 | $85,300,000 |
| Tax Provision | $263,600,000 | $273,800,000 | $135,300,000 | $632,800,000 |
| Other Special Charges | $611,300,000 | $87,800,000 | $20,500,000 | $917,000,000 |
| Impairment Of Capital Assets | $52,900,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $82,200,000 | $57,900,000 | $218,800,000 | $-78,000,000 |
| Gain On Sale Of Security | $-48,300,000 | $-131,300,000 | $-341,600,000 | $-312,800,000 |
| Amortization | $515,000,000 | $446,700,000 | $240,600,000 | $365,900,000 |
| Research And Development | $1,778,600,000 | $1,980,300,000 | $2,445,400,000 | $2,231,100,000 |
| Selling General And Administration | $2,433,600,000 | $2,403,700,000 | $2,549,700,000 | $2,403,600,000 |
| Gain On Sale Of Ppe | - | $0 | $0 | $503,700,000 |
| Gain On Sale Of Business | - | $0 | $0 | $1,505,400,000 |
Fetched: 2026-05-30
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,587,200,000 | $545,900,000 | $217,200,000 | $5,798,800,000 |
| Total Assets | $29,439,500,000 | $28,049,300,000 | $26,844,800,000 | $24,554,100,000 |
| Total Non Current Assets | $20,465,400,000 | $20,592,500,000 | $19,985,500,000 | $14,762,900,000 |
| Other Non Current Assets | $750,600,000 | $560,500,000 | $745,000,000 | $1,529,200,000 |
| Non Current Deferred Assets | $292,500,000 | $324,200,000 | $928,600,000 | $1,226,400,000 |
| Non Current Deferred Taxes Assets | $292,500,000 | $324,200,000 | $928,600,000 | $1,226,400,000 |
| Investmentin Financial Assets | $431,900,000 | $0 | $0 | $705,700,000 |
| Goodwill And Other Intangible Assets | $15,669,600,000 | $16,170,100,000 | $14,582,200,000 | $7,599,100,000 |
| Other Intangible Assets | $9,178,500,000 | $9,691,200,000 | $8,363,000,000 | $1,850,100,000 |
| Current Assets | $8,974,100,000 | $7,456,800,000 | $6,859,300,000 | $9,791,200,000 |
| Other Current Assets | $1,123,300,000 | $752,500,000 | $1,182,000,000 | $1,417,600,000 |
| Inventory | $2,168,100,000 | $2,460,500,000 | $2,527,400,000 | $1,344,400,000 |
| Receivables | $1,867,000,000 | $1,868,800,000 | $2,100,000,000 | $2,136,400,000 |
| Accounts Receivable | $1,867,000,000 | $1,868,800,000 | $2,100,000,000 | $2,136,400,000 |
| Allowance For Doubtful Accounts Receivable | $-3,000,000 | $-2,200,000 | $-2,400,000 | $-2,300,000 |
| Gross Accounts Receivable | $1,870,000,000 | $1,871,000,000 | $2,102,400,000 | $2,138,700,000 |
| Cash Cash Equivalents And Short Term Investments | $3,815,700,000 | $2,375,000,000 | $1,049,900,000 | $4,892,800,000 |
| Cash And Cash Equivalents | $3,008,500,000 | $2,375,000,000 | $1,049,900,000 | $3,419,300,000 |
| Debt | ||||
| Net Debt | $3,278,300,000 | $3,920,800,000 | $5,888,300,000 | $2,861,700,000 |
| Total Debt | $6,577,200,000 | $6,630,300,000 | $7,338,200,000 | $6,614,000,000 |
| Long Term Debt And Capital Lease Obligation | $6,577,200,000 | $4,881,700,000 | $7,188,200,000 | $6,614,000,000 |
| Long Term Debt | $6,286,800,000 | $4,547,200,000 | $6,788,200,000 | $6,281,000,000 |
| Current Debt And Capital Lease Obligation | - | $1,748,600,000 | $150,000,000 | - |
| Current Debt | - | $1,748,600,000 | $150,000,000 | - |
| Other Current Borrowings | - | $1,748,600,000 | $150,000,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,182,700,000 | $11,333,300,000 | $12,045,400,000 | $11,165,700,000 |
| Total Non Current Liabilities Net Minority Interest | $7,833,300,000 | $5,804,500,000 | $8,611,100,000 | $7,892,900,000 |
| Other Non Current Liabilities | $748,500,000 | $732,300,000 | $781,100,000 | $944,200,000 |
| Non Current Deferred Liabilities | $507,600,000 | $190,500,000 | $641,800,000 | $334,700,000 |
| Non Current Deferred Taxes Liabilities | $507,600,000 | $190,500,000 | $641,800,000 | $334,700,000 |
| Current Liabilities | $3,349,400,000 | $5,528,800,000 | $3,434,300,000 | $3,272,800,000 |
| Payables And Accrued Expenses | $2,973,600,000 | $3,404,400,000 | $2,949,200,000 | $2,130,300,000 |
| Payables | $546,800,000 | $972,500,000 | $660,700,000 | $751,400,000 |
| Total Tax Payable | $114,800,000 | $548,300,000 | $257,400,000 | $259,900,000 |
| Accounts Payable | $432,000,000 | $424,200,000 | $403,300,000 | $491,500,000 |
| Other Current Liabilities | - | - | $838,400,000 | $746,900,000 |
| Equity | ||||
| Common Stock Equity | $18,256,800,000 | $16,716,000,000 | $14,799,400,000 | $13,397,900,000 |
| Total Equity Gross Minority Interest | $18,256,800,000 | $16,716,000,000 | $14,799,400,000 | $13,388,400,000 |
| Stockholders Equity | $18,256,800,000 | $16,716,000,000 | $14,799,400,000 | $13,397,900,000 |
| Gains Losses Not Affecting Retained Earnings | $-182,000,000 | $-136,200,000 | $-153,700,000 | $-164,900,000 |
| Other Equity Adjustments | $-182,000,000 | $-136,200,000 | $-153,700,000 | $-164,900,000 |
| Retained Earnings | $20,552,700,000 | $19,259,800,000 | $17,627,600,000 | $16,466,500,000 |
| Other | ||||
| Treasury Shares Number | $23,800,000 | $23,800,000 | $23,800,000 | $23,800,000 |
| Preferred Shares Number | $8,000 | $8,000 | $8,000 | $8,000 |
| Ordinary Shares Number | $146,800,000 | $145,719,340 | $144,900,000 | $144,000,000 |
| Share Issued | $170,600,000 | $169,519,340 | $168,700,000 | $167,800,000 |
| Tangible Book Value | $2,587,200,000 | $545,900,000 | $217,200,000 | $5,798,800,000 |
| Invested Capital | $24,543,600,000 | $23,011,800,000 | $21,737,600,000 | $19,678,900,000 |
| Working Capital | $5,624,700,000 | $1,928,000,000 | $3,425,000,000 | $6,518,400,000 |
| Capital Lease Obligations | $290,400,000 | $334,500,000 | $400,000,000 | $333,000,000 |
| Total Capitalization | $24,543,600,000 | $21,263,200,000 | $21,587,600,000 | $19,678,900,000 |
| Treasury Stock | $2,977,100,000 | $2,977,100,000 | $2,977,100,000 | $2,977,100,000 |
| Additional Paid In Capital | $863,100,000 | $569,400,000 | $302,500,000 | $73,300,000 |
| Capital Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Common Stock | $100,000 | $100,000 | $100,000 | $100,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $290,400,000 | $334,500,000 | $400,000,000 | $333,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $375,800,000 | $375,800,000 | $335,100,000 | $395,600,000 |
| Current Accrued Expenses | $2,426,800,000 | $2,431,900,000 | $2,288,500,000 | $1,378,900,000 |
| Investments And Advances | $431,900,000 | $0 | $0 | $705,700,000 |
| Available For Sale Securities | $431,900,000 | - | - | $705,700,000 |
| Goodwill | $6,491,100,000 | $6,478,900,000 | $6,219,200,000 | $5,749,000,000 |
| Net PPE | $3,320,800,000 | $3,537,700,000 | $3,729,700,000 | $3,702,500,000 |
| Accumulated Depreciation | $-2,931,200,000 | $-2,670,800,000 | $-2,402,500,000 | $-2,165,700,000 |
| Gross PPE | $6,252,000,000 | $6,208,500,000 | $6,132,200,000 | $5,868,200,000 |
| Leases | $143,500,000 | $137,800,000 | $135,700,000 | $107,700,000 |
| Construction In Progress | $163,100,000 | $308,400,000 | $975,400,000 | $888,800,000 |
| Other Properties | $265,400,000 | $356,400,000 | $420,000,000 | $403,900,000 |
| Machinery Furniture Equipment | $3,323,000,000 | $3,239,800,000 | $2,797,400,000 | $2,672,500,000 |
| Buildings And Improvements | $2,140,300,000 | $1,963,700,000 | $1,601,300,000 | $1,592,900,000 |
| Land And Improvements | $216,700,000 | $202,400,000 | $202,400,000 | $202,400,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $807,200,000 | $0 | $0 | $1,473,500,000 |
| Minority Interest | - | - | $0 | $-9,500,000 |
| Other Investments | - | - | - | $1,529,200,000 |
| Inventories Adjustments Allowances | - | - | - | $-21,100,000 |
| Other Inventories | - | - | - | $-21,100,000 |
| Finished Goods | - | - | - | $200,400,000 |
| Work In Process | - | - | - | $751,900,000 |
| Raw Materials | - | - | - | $413,200,000 |
Fetched: 2026-05-30
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,969,200,000 | $2,515,700,000 | $1,235,800,000 | $1,141,100,000 |
| Operating Activities | ||||
| Operating Cash Flow | $2,204,600,000 | $2,875,500,000 | $1,547,200,000 | $1,384,300,000 |
| Cash Flow From Continuing Operating Activities | $2,204,600,000 | $2,875,500,000 | $1,547,200,000 | $1,384,300,000 |
| Operating Gains Losses | $19,300,000 | $12,800,000 | $277,100,000 | $-1,745,800,000 |
| Investing Activities | ||||
| Capital Expenditure | $-235,400,000 | $-359,800,000 | $-311,400,000 | $-243,200,000 |
| Investing Cash Flow | $-1,371,100,000 | $-799,200,000 | $-4,101,000,000 | $1,576,600,000 |
| Cash Flow From Continuing Investing Activities | $-1,371,100,000 | $-799,200,000 | $-4,101,000,000 | $1,576,600,000 |
| Net Other Investing Changes | $42,900,000 | $-4,700,000 | $-11,300,000 | $24,400,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-301,900,000 | $-683,500,000 | $149,300,000 | $-1,747,300,000 |
| Cash Flow From Continuing Financing Activities | $-301,900,000 | $-683,500,000 | $149,300,000 | $-1,747,300,000 |
| Net Other Financing Charges | $-275,000,000 | $-2,200,000 | $6,300,000 | $6,800,000 |
| Repurchase Of Capital Stock | - | $0 | $0 | $-750,000,000 |
| Net Common Stock Issuance | - | $0 | $0 | $-750,000,000 |
| Other | ||||
| Repayment Of Debt | $-1,750,000,000 | $-650,000,000 | $-809,900,000 | $-1,002,200,000 |
| Issuance Of Debt | $1,733,100,000 | $0 | $997,200,000 | $0 |
| Interest Paid Supplemental Data | $264,100,000 | $245,400,000 | $252,200,000 | $262,500,000 |
| Income Tax Paid Supplemental Data | $864,000,000 | $355,100,000 | $740,700,000 | $262,500,000 |
| End Cash Position | $3,008,500,000 | $2,375,000,000 | $1,049,900,000 | $3,419,300,000 |
| Beginning Cash Position | $2,375,000,000 | $1,049,900,000 | $3,419,300,000 | $2,261,400,000 |
| Effect Of Exchange Rate Changes | $101,900,000 | $-67,700,000 | $35,100,000 | $-55,700,000 |
| Changes In Cash | $531,600,000 | $1,392,800,000 | $-2,404,500,000 | $1,213,600,000 |
| Proceeds From Stock Option Exercised | $-10,000,000 | $-31,300,000 | $-44,300,000 | $-1,900,000 |
| Net Issuance Payments Of Debt | $-16,900,000 | $-650,000,000 | $187,300,000 | $-1,002,200,000 |
| Net Long Term Debt Issuance | $-16,900,000 | $-650,000,000 | $187,300,000 | $-1,002,200,000 |
| Long Term Debt Payments | $-1,750,000,000 | $-650,000,000 | $-809,900,000 | $-1,002,200,000 |
| Long Term Debt Issuance | $1,733,100,000 | $0 | $997,200,000 | $0 |
| Net Investment Purchase And Sale | $-1,178,600,000 | $144,700,000 | $2,359,700,000 | $222,500,000 |
| Sale Of Investment | $79,700,000 | $144,700,000 | $7,500,400,000 | $3,671,000,000 |
| Purchase Of Investment | $-1,258,300,000 | $0 | $-5,140,700,000 | $-3,448,500,000 |
| Net Business Purchase And Sale | $0 | $-668,000,000 | $-6,138,000,000 | $990,300,000 |
| Sale Of Business | $0 | $406,800,000 | $788,100,000 | $990,300,000 |
| Purchase Of Business | $0 | $-1,074,800,000 | $-6,926,100,000 | $0 |
| Net Intangibles Purchase And Sale | $-81,600,000 | $-117,500,000 | $-34,400,000 | $-2,900,000 |
| Sale Of Intangibles | $0 | $88,600,000 | $0 | $0 |
| Purchase Of Intangibles | $-81,600,000 | $-206,100,000 | $-34,400,000 | $-2,900,000 |
| Net PPE Purchase And Sale | $-153,800,000 | $-153,700,000 | $-277,000,000 | $342,300,000 |
| Purchase Of PPE | $-153,800,000 | $-153,700,000 | $-277,000,000 | $-240,300,000 |
| Change In Working Capital | $-1,057,600,000 | $-155,200,000 | $-648,700,000 | $-890,300,000 |
| Change In Other Working Capital | $-1,206,100,000 | $-100,200,000 | $-372,900,000 | $-234,300,000 |
| Change In Payables And Accrued Expense | $171,100,000 | $24,600,000 | $-201,600,000 | $-113,400,000 |
| Change In Accrued Expense | $171,100,000 | $24,600,000 | $-201,600,000 | $-113,400,000 |
| Change In Inventory | $-64,700,000 | $-273,800,000 | $-130,900,000 | $-320,200,000 |
| Change In Receivables | $42,100,000 | $194,200,000 | $56,700,000 | $-222,400,000 |
| Changes In Account Receivables | $102,700,000 | $222,300,000 | $61,300,000 | $-203,400,000 |
| Other Non Cash Items | $456,900,000 | $519,200,000 | $304,100,000 | $335,300,000 |
| Stock Based Compensation | $290,800,000 | $291,200,000 | $264,200,000 | $254,100,000 |
| Asset Impairment Charge | $60,800,000 | $60,200,000 | $0 | $119,600,000 |
| Deferred Tax | $361,600,000 | $-158,100,000 | $-305,800,000 | $-168,600,000 |
| Deferred Income Tax | $361,600,000 | $-158,100,000 | $-305,800,000 | $-168,600,000 |
| Depreciation Amortization Depletion | $779,900,000 | $673,200,000 | $494,800,000 | $518,400,000 |
| Depreciation And Amortization | $779,900,000 | $673,200,000 | $494,800,000 | $518,400,000 |
| Amortization Cash Flow | $507,100,000 | $386,500,000 | $240,600,000 | $246,300,000 |
| Amortization Of Intangibles | $507,100,000 | $386,500,000 | $240,600,000 | $246,300,000 |
| Depreciation | $272,800,000 | $286,700,000 | $254,200,000 | $272,400,000 |
| Gain Loss On Investment Securities | $19,300,000 | $101,400,000 | $277,100,000 | $265,900,000 |
| Gain Loss On Sale Of PPE | $0 | $-88,600,000 | $0 | $-503,700,000 |
| Net Income From Continuing Operations | $1,292,900,000 | $1,632,200,000 | $1,161,500,000 | $2,961,600,000 |
| Common Stock Payments | - | $0 | $0 | $-750,000,000 |
| Sale Of PPE | - | $0 | $0 | $582,600,000 |
| Earnings Losses From Equity Investments | - | $0 | $0 | $-2,600,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $-1,505,400,000 |
| Provisionand Write Offof Assets | - | - | - | - |
Fetched: 2026-05-30